GMAB peer analysis
Genmab (GMAB) against its competitors: price, today's move, 1-year return and market value side by side.
- GMAB's peers: ADCT (ADC Therapeutics), ALXO (ALX Oncology), BNTX (BioNTech), CGEN (Compugen), EXEL (Exelixis), INCY (Incyte Genomics), IOVA (Iovance), LEGN (Legend Biotech).
GMAB and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ADCT ADC Therapeutics | $1.28 | -1.54% | -68.16% | $180.05M |
| ALXO ALX Oncology | $1.06 | 3.92% | -27.89% | $137.03M |
| BNTX BioNTech | $81.00 | -0.47% | -20.14% | $20.08B |
| CGEN Compugen | $1.88 | -4.08% | 17.50% | $178.08M |
| EXEL Exelixis | $63.57 | -3.43% | 50.85% | $15.98B |
| INCY Incyte Genomics | $113.91 | -1.69% | 12.43% | $23.22B |
| IOVA Iovance | $6.99 | -4.43% | 209.12% | $3.23B |
| LEGN Legend Biotech | $15.44 | -4.10% | -44.86% | $2.86B |
| MGNX MacroGenics | $1.98 | -0.01% | 39.43% | $126.53M |
| RCUS Arcus Biosciences | $15.50 | -1.77% | -23.34% | $2.23B |
| GMAB Genmab | $50.02 | -2.59% | 63.62% | $30.84B |